Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Aytu BioPharma's share price for the quarter that ended in Dec. 2024 was $1.7. Aytu BioPharma's Shares Outstanding (EOP) for the quarter that ended in Dec. 2024 was 6.17 Mil. Therefore, Aytu BioPharma's market cap for the quarter that ended in Dec. 2024 was $10.49 Mil.
Aytu BioPharma's quarterly market cap
declined
from Jun. 2024 ($17.44 Mil) to Sep. 2024 ($14.45 Mil) and
declined
from Sep. 2024 ($14.45 Mil) to Dec. 2024 ($10.49 Mil).
Aytu BioPharma's annual market cap
declined
from Jun. 2022 ($26.62 Mil) to Jun. 2023 ($8.83 Mil) but then
increased
from Jun. 2023 ($8.83 Mil) to Jun. 2024 ($17.44 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Aytu BioPharma's Enterprise Value for Today is $2.61 Mil.
Aytu BioPharma Market Cap Historical Data
The historical data trend for Aytu BioPharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aytu BioPharma's Market Cap
For the Drug Manufacturers - Specialty & Generic subindustry, Aytu BioPharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aytu BioPharma's Market Cap Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aytu BioPharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Aytu BioPharma's Market Cap falls into.
Aytu BioPharma Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Aytu BioPharma's Market Cap for the fiscal year that ended in Jun. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aytu BioPharma (NAS:AYTU) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Aytu BioPharma Market Cap Related Terms
Thank you for viewing the detailed overview of Aytu BioPharma's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AYTU has been successfully added to your 